PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsDigoxin
Digoxin
Digoxin, Lanoxin (digoxin) is a small molecule pharmaceutical. Digoxin was first approved as Lanoxin on 1982-01-01. It is used to treat anxiety disorders, atrial fibrillation, atrial flutter, cardiogenic shock, and heart failure amongst others in the USA. The pharmaceutical is active against sodium/potassium-transporting ATPase subunit alpha-1. In addition, it is known to target solute carrier organic anion transporter family member 4C1.
Download report
Favorite
Searched
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
mental disordersD001523
Trade Name
FDA
EMA
Digoxin, Lanoxin (discontinued: Digoxin, Lanoxicaps, Lanoxin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Digoxin
Tradename
Company
Number
Date
Products
LANOXINADVANZ PHARMAN-020405 RX1997-09-30
3 products, RLD, RS
LANOXINCovis PharmaN-009330 RX1982-01-01
1 products, RLD, RS
LANOXIN PEDIATRICCovis PharmaN-009330 RX1982-01-01
1 products, RLD, RS
DIGOXINHikma PharmaceuticalsN-021648 RX2004-08-26
1 products, RLD, RS
Show 2 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
digifabBiologic Licensing Application2015-11-06
digoxANDA2019-11-01
digoxinANDA2025-01-14
lanoxinNew Drug Application2024-12-31
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
atrial fibrillationEFO_0000275D001281I48.0
heart failureHP_0001635D006333I50
cardiogenic shock—D012770R57.0
atrial flutterEFO_0003911D001282—
low cardiac output—D002303—
supraventricular tachycardiaHP_0004755D013617I47.1
anxiety disordersEFO_0006788D001008F41.1
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C01: Cardiac therapy drugs
— C01A: Cardiac glycosides
— C01AA: Digitalis glycosides
— C01AA05: Digoxin
HCPCS
Code
Description
J1160
Injection, digoxin, up to 0.5 mg
J1162
Injection, digoxin immune fab (ovine), per vial
Clinical
Clinical Trials
258 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pre-eclampsiaD011225EFO_0000668O14—1———1
EclampsiaD004461HP_0100601O15—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C501————1
Bacterial infectionsD001424—A491————1
EpilepsyD004827EFO_0000474G40.91————1
Type 2 diabetes mellitusD003924EFO_0001360E111————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDigoxin
INNdigoxin
Description
Digoxin is a cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small. It has a role as an epitope, an anti-arrhythmia drug, a cardiotonic drug and an EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor. It is a cardenolide glycoside and a steroid saponin. It is a conjugate acid of a digoxin(1-).
Classification
Small molecule
Drug classfluoroquinolone derivatives, nonantibacterial indication (e.g., antineoplastic antibiotics)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6C[C@@H](O)[C@]7(C)[C@@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O
Identifiers
PDB—
CAS-ID20830-75-5
RxCUI—
ChEMBL IDCHEMBL1751
ChEBI ID4551
PubChem CID2724385
DrugBankDB00390
UNII ID73K4184T59 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Digoxin
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 32,655 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
21,760 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use